The DOI matches its Crossref record; 39 of the 41 references it cites were found in a registry or an index.
Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: a retrospective population-based cohort study
Abstract
Background Little is known about how long the BCG vaccine protects against tuberculosis. We assessed the long-term vaccine effectiveness (VE) in Norwegian-born individuals.Methods In this retrospective population-based cohort study, we studied Norwegian-born individuals aged 12-50 years who were tuberculin skin test (TST) negative and eligible for BCG vaccination as part of the last round of Norway's mandatory mass tuberculosis screening and BCG vaccination programme between 1962 and 1975. We excluded individuals who had tuberculosis before or in the year of screening and those with unknown TST and BCG status. We obtained TST and BCG information and linked it to the National Tuberculosis Register, population and housing censuses, and the population register for emigrations and deaths. We followed individuals up to their first tuberculosis episode, emigration, death, or Dec 31, 2011. We used Cox regressions to estimate VE against all tuberculosis and just pulmonary tuberculosis by time since vaccination, adjusted for age, time, county-level tuberculosis rates, and demographic and socioeconomic indicators.Findings Median follow-up was 41 years (IQR 32-49) for 83 421 BCG-unvaccinated and 44 years (41-46) for 297 905 vaccinated individuals, with 260 tuberculosis episodes. Tuberculosis rates were 3·3 per 100 000 person-years in unvaccinated and 1·3 per 100 000 person-years in vaccinated individuals. The adjusted average VE during 40 year follow-up was 49% (95% CI 26-65), although after 20 years, the VE was not significant (up to 9 years VE [excluding tuberculosis episodes in the first 2 years] 61% [95% CI 24-80]; 10-19 years 58% [27-76]; 20-29 years 38% [-32 to 71]; 30-40 years 42% [-24 to 73]). VE against pulmonary tuberculosis up to 9 years (excluding tuberculosis episodes in the first 2 years) was 67% (95% CI 27-85), 10-19 years was 63% (32-80), 20-29 years was 50% (-19 to 79), and 30-40 years was 40% (-46 to 76).Interpretation Findings are consistent with long-lasting BCG protection, but waning of VE with time. The vaccine could be more cost effective than has been previously estimated Funding Norwegian Institute of Public Health and London School of Hygiene & Tropical Medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“While this mechanism is still under investigation, most studies show that these effects tend to wane after 15 to 20 years [5,6].”
From Bacille Calmette-Guérin Vaccination in Infancy Does Not Protect Against Coronavirus Disease 2019 (COVID-19): Evidence From a Natural Experiment in Sweden (2021) · cites this paper as [6]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Multiple Imputation for Nonresponse in Surveys.
Lynn, P., & Rubin, D. B. (1988) · The Statistician · doi:10.2307/2348774 · Cited by 2,329
Flexible Imputation of Missing Data
van Buuren, S. (2012) · doi:10.1201/b11826 · Cited by 2,022
Variation in protection by BCG: implications of and for heterologous immunity
Fine, P. E. M. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92348-9 · Cited by 1,380
Uplekar, M., Weil, D., Lonnroth, K., Jaramillo, E., Lienhardt, C., Dias, H. M., Falzon, D., Floyd, K., Gargioni, G., Getahun, H., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60570-0 · Cited by 1,117
Trunz, B. B., Fine, P., & Dye, C. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68507-3 · Cited by 1,114
Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials
Mangtani, P., Abubakar, I., Ariti, C., Beynon, R., Pimpin, L., Fine, P. E. M., Rodrigues, L. C., Smith, P. G., Lipman, M., Whiting, P. F., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit790 · Cited by 995
Self-citationTowards tuberculosis elimination: an action framework for low-incidence countries
Lönnroth, K., Migliori, G. B., Abubakar, I., D'Ambrosio, L., de Vries, G., Diel, R., Douglas, P., Falzon, D., Gaudreau, M.-A., Goletti, D., et al. (2015) · European Respiratory Journal · doi:10.1183/09031936.00214014 · Cited by 778
Self-citationColditz, G. A., Berkey, C. S., Mosteller, F., Brewer, T. F., Wilson, M. E., Burdick, E., & Fineberg, H. V. (1995) · Pediatrics · doi:10.1542/peds.96.1.29 · Cited by 763
Protective Effect of BCG against Tuberculous Meningitis and Miliary Tuberculosis: A Meta-Analysis
RODRIGUES, L. C., DIWAN, V. K., & WHEELER, J. G. (1993) · International Journal of Epidemiology · doi:10.1093/ije/22.6.1154 · Cited by 650
Self-citation
Research works printed but not linked: 2
- 2004, BCG vaccine. WHO position paper, Wkly Epidemiol Rec, 79, 27
- Gernez-Rieux, 1973, Protection conférée par le BCG pendant les vingt années suivant la vaccination, Bull World Health Organ, 48, 139
Cited by
Trained immunity — basic concepts and contributions to immunopathology
Ochando, J., Mulder, W. J. M., Madsen, J. C., Netea, M. G., & Duivenvoorden, R. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00633-5 · Cited by 453
What Have We Learnt about BCG Vaccination in the Last 20 Years?
Dockrell, H. M., & Smith, S. G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01134 · Cited by 259
100 years of Mycobacterium bovis bacille Calmette-Guérin
Lange, C., Aaby, P., Behr, M. A., Donald, P. R., Kaufmann, S. H. E., Netea, M. G., & Mandalakas, A. M. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00403-5 · Cited by 248
Martinez, L., Cords, O., Liu, Q., Acuna-Villaorduna, C., Bonnet, M., Fox, G. J., Carvalho, A. C. C., Chan, P.-C., Croda, J., Hill, P. C., et al. (2022) · The Lancet Global Health · doi:10.1016/s2214-109x(22)00283-2 · Cited by 210
Moliva, J. I., Turner, J., & Torrelles, J. B. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00407 · Cited by 188
Metadata
- Authors
- Nguipdop-Djomo, P., Heldal, E., Rodrigues, L. C., Abubakar, I., & Mangtani, P.
- Affiliations
- Norwegian Institute of Public Health (NO)
- London School of Hygiene & Tropical Medicine (GB)
- University College London (GB)
- Venue
- The Lancet Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2016-02
- Volume
- 16
- Issue
- 2
- Pages
- 219-226
- ISSN
- 1473-3099 (ISSN-L)
- OpenAlex
- W2181978203
- Cited by
- 202
- References
- 41
- Citations by year
- 2026: 14 · 2025: 15 · 2024: 26 · 2023: 13 · 2022: 18 · 2021: 30 · 2020: 24 · 2019: 21 · 2018: 13 · 2017: 17 · 2016: 9
- FWCI
- 10.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Funders
- National Institute for Health and Care Research (SRF-2011-04-001, 08/17/01, 08/16/01)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Keywords
- BCG vaccine, long-term vaccine protection, time since vaccination, pulmonary tuberculosis, tuberculosis incidence, tuberculin skin test, tuberculosis prevention, tuberculosis mortality, tuberculosis control policy, Norway
- MeSH terms
- Adolescent, Adult, Age Factors, BCG Vaccine, Child, Female, Humans, Male, Mass Screening, Middle Aged, Mycobacterium bovis, Norway, Population Surveillance, Retrospective Studies, Socioeconomic Factors, Time Factors, Tuberculosis, Cohort Studies, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: a retrospective population-based cohort study. https://app.cochat.ai/papers/10.1016/s1473-3099(15)00400-4
- The paper
- Nguipdop-Djomo, P., Heldal, E., Rodrigues, L. C., Abubakar, I., & Mangtani, P. (2016). Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: a retrospective population-based cohort study. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(15)00400-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.